Art. 101 Directive (EU) 2001/83

In forcesince 20 Jan 2011cited 13×
1.

Member States shall operate a pharmacovigilance system for the fulfilment of their pharmacovigilance tasks and their participation in Union pharmacovigilance activities.

The pharmacovigilance system shall be used to collect information on the risks of medicinal products as regards patients’ or public health. That information shall in particular refer to adverse reactions in human beings, arising from use of the medicinal product within the terms of the marketing authorisation as well as from use outside the terms of the marketing authorisation, and to adverse reactions associated with occupational exposure.

2.

Member States shall, by means of the pharmacovigilance system referred to in paragraph 1, evaluate all information scientifically, consider options for risk minimisation and prevention and take regulatory action concerning the marketing authorisation as necessary. They shall perform a regular audit of their pharmacovigilance system and report the results to the Commission on 21 September 2013 at the latest and then every 2 years thereafter.

3.

Each Member State shall designate a competent authority for the performance of pharmacovigilance tasks.

4.

The Commission may request Member States to participate, under the coordination of the Agency, in international harmonisation and standardisation of technical measures in relation to pharmacovigilance.

The 10 that are cited most themselves, of 13.

  • Judgment of the Court (Grand Chamber) of 23 January 2018. F. Hoffmann-La Roche Ltd and Others v Autorità Garante della Concorrenza e del MerDecision

    Article 101(1) of amended Directive 2001/83 provides: ‘Member States shall operate a pharmacovigilance system for the fulfilment of their pharmacovigilance tasks and their participation in Union pharmacovigilance activities. The …

    23 Jan 2018 · 62016CJ0179

  • Directive (EU) 2004/27Lawamends

  • Commission Implementing Regulation (EU) No 520/2012 of 19 June 2012 on the performance o…11Law

    … рисковете, които носят лекарствените продукти, посочена в член 101, параграф 1, втора алинея от Директива 2001/83/ЕО; в) подаването на …

  • Judgment of the Court (Fourth Chamber) of 8 October 2020. kohlpharma GmbH v Bundesrepublik Deutschland.Decision

    Title IX, entitled ‘Pharmacovigilance’, of Directive 2001/83 includes Article 101 of that directive, which provides: ‘1. Member States shall operate a pharmacovigilance system for the fulfilment of their pharmacovigilance tasks and …

    8 Oct 2020 · 62019CJ0602

  • Opinion of Advocate General Saugmandsgaard Øe delivered on 25 July 2018. Novartis Farma SpA v Agenzia Italiana del Farmaco (AIFA) and OthersDecision

    To my mind, where the repackaging in several individual doses of a medicinal product that falls within the scope of Directive 2001/83 does not involve the medicinal substance being modified, the product repackaged in that way continues to …

    25 Jul 2018 · 62017CC0029

  • Judgment of the Court (First Chamber) of 21 November 2018. Novartis Farma SpA v Agenzia Italiana del Farmaco (AIFA) and Others.Decision

    Article 101(1) of that directive provides: ‘Member States shall operate a pharmacovigilance system for the fulfilment of their pharmacovigilance tasks and their participation in Union pharmacovigilance activities. The pharmacovigilance …

    21 Nov 2018 · 62017CJ0029

  • Judgment of the General Court (Fifth Chamber, Extended Composition) of 15 May 2024. Fresenius Kabi Austria GmbH and Others v European CommisDecision

    Secondly, Article 101(1) of Directive 2001/83, as amended, describes the objective of the pharmacovigilance system and the scope of the information which it serves to collect. It follows from that provision that the concept of ‘risks … …

    15 May 2024 · 62022TJ0416

  • Judgment of the Court (Third Chamber) of 25 November 2021. Delfarma Sp. z o.o. v Prezes Urzędu Rejestracji Produktów Leczniczych, Wyrobów MeDecision

    Title IX of Directive 2001/83, entitled ‘Pharmacovigilance’, comprises Articles 101 to 108 thereof.

    25 Nov 2021 · 62020CJ0488

  • Opinion of Advocate General Saugmandsgaard Øe delivered on 21 September 2017. F. Hoffmann-La Roche Ltd and Others v Autorità Garante della CDecision

    It matters little that Regulation No 726/2004, like Directive 2001/83 did not extend the pharmacovigilance obligations to off-label uses of medicinal products until July 2012, [See points 12 to 14 of this Opinion. See also the second …

    21 Sep 2017 · 62016CC0179

  • Cour de cassation, civile, Chambre commerciale, 25 juin 2025, 23-13.391, Publié au bulletinDecision

    Ensuite, selon l'article 101, paragraphe 1, second alinéa, de la directive 2001/83, les médicaments sont soumis à un système de pharmacovigilance qui sert à recueillir des informations concernant les risques qu'ils présentent pour la …

    25 Jun 2025 · JURITEXT000051823951